Suvemcitug for injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Jiangsu Simcere Biopharmaceutical Co., Ltd.
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: With paclitaxel, liposomal doxorubicin or topotecan for adults with recurrent ovarian, fallopian tube or primary peritoneal cancer who have received no more than one systemic treatment after becoming platinum-resistant.
Indication source and scope: Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
Prescribing-information limitations: Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to adults with recurrent ovarian, fallopian tube or primary peritoneal cancer who have received no more than one systemic treatment after becoming platinum-resistant.
Insurance period: 2026-01-01 to 2027-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions